Filing Details
- Accession Number:
- 0001415889-24-008771
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-20 18:00:25
- Reporting Period:
- 2024-03-18
- Accepted Time:
- 2024-03-20 18:00:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1798749 | Aerovate Therapeutics Inc. | AVTE | Pharmaceutical Preparations (2834) | 831377888 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1868997 | Hunter Gillies | C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham MA 02451 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-18 | 4,000 | $1.74 | 7,251 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-03-18 | 3,000 | $2.14 | 10,251 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-18 | 6,387 | $25.81 | 3,864 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-18 | 613 | $26.40 | 3,251 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-03-18 | 4,000 | $0.00 | 4,000 | $1.74 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-03-18 | 3,000 | $0.00 | 3,000 | $2.14 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 4,036 | 2030-09-03 | No | 4 | M | Direct | |
| 98,510 | 2031-04-01 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.25 to $26.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
- A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.
Billionaire Hedge Funds
